TPN-101, 200 mg/day for Progressive Supranuclear Palsy (PSP)

Phase-Based Progress Estimates
Progressive Supranuclear Palsy (PSP)+1 More
TPN-101, 200 mg/day - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug to see if it is safe and tolerated by people with PSP.

Eligible Conditions
  • Progressive Supranuclear Palsy (PSP)

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 48 weeks

48 weeks
Assess the clinical effect of TPN-101 as measured by changes in score on the Progressive Supranuclear Palsy Rating Scale (PSPRS)
Assess the pharmacodynamic effect of TPN-101 on neurodegeneration as measured by changes in the levels of CSF and blood neurofilament light (NfL)
Cerebrospinal fluid shunts procedure
Assess the safety and tolerability of TPN-101 in patients with progressive supranuclear palsy (PSP)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

TPN-101, Dose B
1 of 4
TPN-101, Dose A
1 of 4
TPN-101, Dose C
1 of 4
1 of 4

Experimental Treatment

Non-Treatment Group

40 Total Participants · 4 Treatment Groups

Primary Treatment: TPN-101, 200 mg/day · Has Placebo Group · Phase 2

TPN-101, Dose B
Experimental Group · 1 Intervention: TPN-101, 200 mg/day · Intervention Types: Drug
TPN-101, Dose A
Experimental Group · 1 Intervention: TPN-101, 100 mg/day · Intervention Types: Drug
TPN-101, Dose C
Experimental Group · 1 Intervention: TPN-101, 400 mg/day · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks

Who is running the clinical trial?

Transposon Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
56 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have symptoms of PSP for less than 5 years.
Patient must reside outside a skilled nursing facility or dementia care facility at the time of Screening, and admission to such a facility must not be planned

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
How old are they?
18 - 6550.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria50.0%
Met criteria50.0%